These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 25853466)
1. Will purple become the new orange? The new FDA purple book for biologics: what does the future hold? Sabatelli AD; Alpha-Cobb CJ Pharm Pat Anal; 2015; 4(2):63-8. PubMed ID: 25853466 [No Abstract] [Full Text] [Related]
2. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009. Carver KH; Elikan J; Lietzan E Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247 [TBL] [Abstract][Full Text] [Related]
4. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related]
5. FDA's role in administering the Hatch-Waxman Act. Malkin BJ Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575 [No Abstract] [Full Text] [Related]
6. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009. Dougherty MP Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541 [TBL] [Abstract][Full Text] [Related]
7. The History and Political Economy of the Hatch-Waxman Amendments. Lietzan E Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922 [No Abstract] [Full Text] [Related]
8. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Hennessy S; Leonard CE; Platt R Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450 [TBL] [Abstract][Full Text] [Related]
9. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law. Dinh TQ Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027 [No Abstract] [Full Text] [Related]
10. Biosimilars: the need, the challenge, the future: the FDA perspective. Epstein MS; Ehrenpreis ED; Kulkarni PM; Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160 [TBL] [Abstract][Full Text] [Related]
11. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals. Blackstone EA; Fuhr JP Future Med Chem; 2010 Nov; 2(11):1641-9. PubMed ID: 21428836 [TBL] [Abstract][Full Text] [Related]
12. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Grabowski HG; Kyle M; Mortimer R; Long G; Kirson N Health Aff (Millwood); 2011 Nov; 30(11):2157-66. PubMed ID: 22068409 [TBL] [Abstract][Full Text] [Related]
13. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics. Wright EE; Blevins TC; Reed B; Pollom RD J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404 [TBL] [Abstract][Full Text] [Related]
14. SuperGenerics: a better alternative for biogenerics. Charles SA Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591 [No Abstract] [Full Text] [Related]
15. Takings issues in the approval of generic biologics. Yoo JC Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853 [No Abstract] [Full Text] [Related]
16. US biotech prepares to fight generic biologics. Reid B Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820 [No Abstract] [Full Text] [Related]
17. The market for follow-on biologics: how will it evolve? Grabowski H; Cockburn I; Long G Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725 [TBL] [Abstract][Full Text] [Related]
18. Foreword: Follow-on Biologics: Implementation Challenges and Opportunities. Paradise J Seton Hall Law Rev; 2011; 41(2):501-10. PubMed ID: 21739728 [TBL] [Abstract][Full Text] [Related]
19. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. Hao J; Rodriguez-Monguio R; Seoane-Vazquez E PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277 [TBL] [Abstract][Full Text] [Related]